External validation of the hit expert probability (HEP) score

Thrombosis and Haemostasis

Volumn 113, Issue 3, 2015, Pages 633-640

  Joseph, Lee ^a   Gomes, Marcelo P V ^a   Al Solaiman, Firas ^a   St John, Julie ^a   Ozaki, Asuka ^a   Raju, Manjunath ^a   Dhariwal, Manoj ^a   Kim, Esther S H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Heparins; Thrombocytopenia; Thrombosis

Indexed keywords

HEPARIN; ANTIBODY; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; SEROTONIN; THROMBOCYTE FACTOR 4;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASSESSMENT OF HUMANS; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HIT EXPERT PROBABILITY SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROTONIN RELEASE; VALIDATION STUDY; AGED; BLOOD; CHEMICALLY INDUCED; DECISION SUPPORT SYSTEM; IMMUNOLOGY; MIDDLE AGED; OBSERVER VARIATION; PROBABILITY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA; UNITED STATES;

AGED; ANTIBODIES; ANTICOAGULANTS; AREA UNDER CURVE; BIOMARKERS; DECISION SUPPORT TECHNIQUES; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; OHIO; PLATELET FACTOR 4; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEROTONIN; THROMBOCYTOPENIA;

EID: 84924180458     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-05-0472     Document Type: Article

References (14)

1. Oliveira GB CE, Becker RC, Honeycutt EF, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94–102.
2. Lo GK SC, Warkentin TE. What is the potential for overdiagnosis of heparin-in-duced thrombocytopenia? Am J Hematol 2007; 82: 1037–1043.
3. Lo GK JD, Warkentin TE, Sigouin CS, et al. Evaluation of pretest clinical score (4 T s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759–765.
4. Crowther MA CD, Albert M, Williamson D, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 2010; 25: 287–293.
5. Denys B S V, Phillippé J, Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res 2008; 123: 137–145.
6. Pouplard C G P, Fouassier M, Ternisien C, et al. Prospective evaluation of the 4Ts score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2007; 5: 1373–1379.
7. Bryant A LJ, Austin S, Joseph JE. Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T_s score and particle gel immunoassay. Br J Haematol 2008; 143: 721–726.
8. Lillo-Le Louët A B P, Alhenc-Gelas M, Le Beller C, et al. Diagnostic score for he-parin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004; 2: 1882–1888.
9. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytope-nia based on broad expert opinion. J Thromb Haemost 2010; 8: 2642–2650.
10. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (RED-Cap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.
11. Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-in-duced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 9: 2498–2500.
12. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202–204.
13. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160: 635–641.
14. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.